RxDoctor Payments Data

Matthew Hutchins, MD

Interventional Cardiology · Cincinnati, OHNPI 1114926813

Payments from drug & device makers

$658in general payments, 2019–2025

Across 32 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$263
  • Lemaitre Vascular, Inc.$70
  • Johnson & Johnson$45
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$39
  • Vital Connect, Inc$37
  • Pfizer$30
  • plus $175 from 10 others

What the payments were for

  • Food & beverage$64698%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$658 in reported general payments places this provider in the 10th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$100,857
Medicare patients
1,099
Services billed
1,793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban305$328,090
Repatha SureclickEvolocumab192$173,999
EntrestoSacubitril/Valsartan122$118,375
XareltoRivaroxaban61$59,813
JardianceEmpagliflozin30$29,287
Praluent PenAlirocumab31$21,891
Metoprolol Succinate1,056$11,239
Atorvastatin Calcium1,142$10,003
Valsartan290$8,324
Ranolazine ErRanolazine77$7,547
Prasugrel Hcl41$6,745
Ezetimibe311$5,207
Rosuvastatin Calcium420$5,189
Olmesartan Medoxomil194$4,631
ClopidogrelClopidogrel Bisulfate350$3,250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$328,090305 claims
NovartisEntresto$263$118,375122 claims
Johnson & JohnsonXarelto$45$59,81361 claims
Boehringer IngelheimJardiance$24$29,28730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →